Mylan Voluntary Globally Recalls 2 Lots of Levoleucovorin (250mg/25ml) Injection Used to Prevent Harmful Effects of Methotrexate

 Mylan Voluntary Globally Recalls 2 Lots of Levoleucovorin (250mg/25ml) Injection Used to Prevent Harmful Effects of Methotrexate

Mylan Voluntary Globally Recalls 2 Lots of Levoleucovorin (250mg/25ml) Injection Used to Prevent Harmful Effects of Methotrexate

Shots:

  • Mylan has recalled two lots of Levoleucovorin (250mg/25ml) injection to the consumer level having a lot number APB032 & APB033 due to presence of foreign particle as copper salt discovered during a 12-month stability testing
  • The voluntary recall is done for the lots of Levoleucovorin, distributed between August 2017 to July 2018 in the US and is conducted within the knowledge of the US FDA
  • Levoleucovorin (250mg/25ml) is a single-use vial antidote for dihydrofolate reductase by methotrexate and used as a combination therapy with 5-fluorouracil for advanced metastatic colorectal cancer, developed by Alidac Pharmaceuticals

Click here to read full press release/ article | Ref: Mylan | Image: Daily Post India

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post